NASDAQ · Biotechnology

AzurRx BioPharma, Inc. (AZRX) Stock

$3.45 +2.07% NASDAQ: AZRX Healthcare

AzurRx BioPharma, Inc., a Brooklyn, New York-based company employing 12 full-time individuals, focuses on the discovery and advancement of non-systemic biological treatments for various gastrointestinal conditions. Its current developmental portfolio comprises two therapeutic protein assets: MS1819 and AZX1101.

Valuation

MetricValue
Price$3.45
Market Cap$3.43M
P/E Ratio-0.73
P/B Ratio0.65
P/S Ratio46.10
EPS (TTM)$-4.16
52-Week High$26.30
52-Week Low$2.68
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-49.81%
ROA-18.21%
ROCE-31.12%
Gross Margin0.00%
Operating Margin—
Net Margin—
Debt/Equity0.11
Current Ratio0.16

Annual Financials (USD)

Metric20182019202020242025
Revenue$0$0$0$0$0
Operating Profit$-13.0M$-15.0M$-26.0M$-16.0M$-7.0M
Net Profit$-14.0M$-15.0M$-33.0M$-18.0M$-7.0M
EPS$-8.77$-6.77$-5.90$-5.33$-4.16
Op Margin————-19540.0%

Balance Sheet (USD)

Metric20182019202020242025
Total Assets$7.0M$9.0M$0$85.0M$49.0M
Total Liabilities$3.0M$4.0M$0$28.0M$20.0M
Cash$1.0M$0$0$0$1.0M
Borrowings$0$2.0M$0$0$2.0M

Latest News

TikTok settling three teen social media lawsuits ahead of trial Reuters · Aug 3, 2026 Masimo Appoints Tim Benner as President PR Newswire · Aug 3, 2026 3 of Wall Street’s Favorite Stocks to Target This Week StockStory · Aug 3, 2026 Rush Enterprises Insider Sold Shares Worth $365,243, According to a Recent SEC Filing MT Newswires · Aug 3, 2026 Stoke Therapeutics Q2 Earnings Call Highlights MarketBeat · Aug 3, 2026

Cash Flow (USD)

Metric20182019202020242025
Operating Cash Flow$-11.0M$-14.0M$-11.0M$-9.0M$-6.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$12.0M$13.0M$33.0M$6.0M$6.0M
Net Cash Flow$1.0M$-1.0M$6.0M$-4.0M$1.0M
Free Cash Flow$-11.0M$-14.0M$-11.0M$-9.0M$-6.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.02
EV / EBITDA3.11
FCF Yield-194.33%
Quick Ratio0.16
Interest Coverage10.70
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BCELAtreca, Inc. $0.09 -1.32% -0.04 $3.57M 0.00%
CYTOAltamira Therapeutics Ltd. $0.30 +100.00% -0.02 $1.13M 0.00%
GRTSGritstone bio, Inc. $0.03 -31.78% -0.03 $3.80M 0.00%
IDRAIdera Pharmaceuticals, Inc. $0.43 -21.82% -0.06 $0 0.00%
LSTA $1.44 -13.77% -1.66 $13.11M 0.00%

About AzurRx BioPharma, Inc.

AzurRx BioPharma, Inc., a Brooklyn, New York-based company employing 12 full-time individuals, focuses on the discovery and advancement of non-systemic biological treatments for various gastrointestinal conditions. Its current developmental portfolio comprises two therapeutic protein assets: MS1819 and AZX1101. MS1819 is an acid-stable lipase enzyme (LIP2), originating from Yarrowia lipolytica, which AzurRx is genetically engineering to address exocrine pancreatic insufficiency (EPI). EPI is a debilitating disorder often seen in patients with chronic pancreatitis (CP) and cystic fibrosis (CF). The second promising compound, AZX1101, is a recombinant beta-lactamase combination sourced from bacteria. This asset is being engineered with a dual aim: to avert nosocomial infections caused by resistant bacterial strains, especially after intravenous beta-lactam antibiotic administration, and to mitigate antibiotic-associated diarrhea (AAD).

AzurRx BioPharma, Inc. is headquartered in US.

AzurRx BioPharma, Inc. (AZRX) stock trades at $3.45 with a market capitalization of $3.43M. The stock is valued at a price-to-earnings (P/E) ratio of -0.73, price-to-book of 0.65, price-to-sales of 46.10. Over the past 52 weeks the stock has ranged between $2.68 and $26.30, and currently trades 86.9% below its 52-week high.

On profitability, AzurRx BioPharma, Inc. generates a return on equity (ROE) of -49.81%, return on capital employed of -31.12%.

Official website: enterothera.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides